Peter Svennilson founded The Column Group in 2007 and has worked in venture capital and finance for over 35 years. He was the Chairman of Aragon Pharmaceuticals from startup until it was sold to Johnson & Johnson in 2013 and was the Chairman of Seragon Pharmaceuticals until it was sold to Genentech/ Roche in 2014. Mr. Svennilson was a Board Director of NGM Biopharmaceuticals (“NGM” on NASDAQ) and Constellation Pharmaceuticals (“CNST” on NASDAQ). He was also a Board Observer of Arcus Biosciences until the company went public in 2018 (“RCUS” on NYSE).
Prior to TCG, he was the Founder and Managing Partner of Three Crowns Capital where he helped finance large parts of the venture capital for biotech companies such as Tularik, Rosetta, PTC, Chemocentryx, Rinat, Tercica, Somalogic, Infinity and Fiveprime. Prior to Three Crowns Capital he was the Associate Managing Director in charge of European Investment Banking Origination at Nomura in London. Mr. Svennilson is a Trustee at The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received an M.B.A. from the Stockholm School of Economics and Finance.
Board of Directors: Carmot Therapeutics